"Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity."@en . "For treatment of organ transplant recipients, prevention of organ rejection"@en . . "Muromonab-CD3"@en . "0.8 hours (mammalian reticulocytes, in vitro)"@en . "140608-64-6"@en . . . . . . . " "@en . . "approved"@en . . . "investigational"@en . "Humans and other mammals"@en . . "Muromonab"@en . . . . . "Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a)."@en . . "Anti-CD3"@en . . .